Šalis: Malta
kalba: anglų
Šaltinis: Medicines Authority
ALLOPURINOL
Hennig Arzneimittel GmbH & Co KG Liebigstrasse 1-2, D-65439 Flörsheim am Main, Germany
M04AA01
ALLOPURINOL 100 mg
TABLET
ALLOPURINOL 100 mg
POM
ANTIGOUT PREPARATIONS
Withdrawn
2006-08-30
1 Dear Patient! Please read this leaflet carefully as it contains important information which you should know before taking your medicine. If you have any questions, please ask your doctor or pharmacist. PATIENT INFORMATION LEAFLET CELLIDRIN ® 100 MG ACTIVE SUBSTANCE: ALLOPURINOL COMPOSITION _Pharmaceutically active components: _ 1 Cellidrin 100 mg tablet contains 100 mg allopurinol. _Other components:_ Lactose monohydrate, povidone, macrogol, magnesium stearate, maize starch, microcrystalline cellulose, croscarmellose sodium, 70% Sorbitol (crystallising) solution, highly dispersed silicon dioxide PHARMACEUTICAL FORM Packs of 100 tablets Cellidrin 100 mg inhibits the formation of uric acid. HENNIG ARZNEIMITTEL GmbH & Co. KG Liebigstr. 1-2 DE-65439 Flörsheim am Main Phone: +49 6145 508-0 Fax: +49 6145 508-140 INDICATIONS _Adults _ Hyperuricaemia (elevated uric acid levels in the blood) with blood uric acid levels of approx. 500 µmol/l (8.5 mg/100 ml) and over, not controllable by dietary changes. Diseases caused by increased uric acid in the blood, particularly gout, urate nephropathy (uric acid-induced kidney damage) and urate nephrolithiasis (uric acid stones). Secondary hyperuricaemia of various origins (increased uric-acid blood levels caused by other diseases). Prevention of calcium oxalate stones in patients with raised uric-acid blood levels. _Children _ Urate nephropathy (uric acid-induced kidney damage) in patients undergoing treatment for leukaemia. Secondary hyperuricaemia of various origins (increased uric-acid blood levels caused by other disea Perskaitykite visą dokumentą
Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cellidrin ® 100 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 Cellidrin ® 100 mg tablet contains 100 mg allopurinol. 3. PHARMACEUTICAL FORM Tablet 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _Adults_ - Hyperuricaemia with uric acid serum levels of approx. 500 µmol/l (8.5 mg/100 ml) and over, not controllable by dietary changes. - Diseases caused by increased uric acid in the blood, particularly gout, urate nephropathy and urate nephrolithiasis. - Secondary hyperuricaemia of various aetiology. - Prophylaxis of calcium oxalate calculi in patients with elevated uric acid levels. _ _ _Children_ - Urate nephropathy in children undergoing leukaemia treatment. - Secondary hyperuricaemia of various aetiology. - Congenital enzyme deficiency disorders such as Lesch-Nyhan syndrome (partial or total hypoxanthine-guanine phosphoribosyl transferase deficiency) and adeninephosphoribosyl transferase deficiency. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults _ Depending on the patient's current uric-acid serum levels, 1 to 3 tablets Cellidrin 100 mg (which corresponds to 100 to 300 mg allopurinol) to be taken daily. In some cases the dose can be increased to 6 to 8 tablets Cellidrin 100 mg (which corresponds to 600 to 800 mg allopurinol). A dose increase requires that the patient's oxipurinol serum levels be checked as the latter must not exceed 15 µg/ml (100 µmol). For better tolerability a single dose should not exceed 3 Cellidrin 100 mg tablets (corresponding to 300 mg allopurinol). _ _ _ _ Page 2 of 7 Perskaitykite visą dokumentą